2016 Fiscal Year Final Research Report
Establishment of cerebral embolic stroke treatment by Staphylokinase
| Project/Area Number |
26462149
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | Hirosaki University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | Staphylokinase / Cerebral infarction / Embolic stroke |
|---|
| Outline of Final Research Achievements |
Four hundred microgram per kg Staphylokinase (SAK) reduced cerebral infarction same as clinical dose of t-PA. The rate of respiratory trouble and mortality in SAK groups were significantly smaller than t-PA group. Reduction of MMP-9 and preservation of blood brain barrier were detected. And intra-arterial injection of VEGF antagonist significantly reduced cerebral infarction volume and preserve neural function. Reduction of IP3KA and Occludin were detected. High dose SAK is an alternative to t-PA in the treatment of embolic ischemic stroke. Combination therapy of SAK and VEGF antagonist achieved synergism in ischemic stroke treatment.
|
| Free Research Field |
脳梗塞
|
